Acer Therapeutics Management
CEO & Founder
Chris Schelling has 18 years of biotech and pharma strategic and orphan drug expertise. Prior to founding Acer, he was Executive Director of Strategic Marketing at BioMarin Pharmaceutical (BMRN), where he was instrumental in the development and commercialization of the company’s phenylketonuria (PKU) franchise. Previously, he held roles at Abgenix, Cell Therapeutics, Stanford Research Institute Consulting, and Organon.
Robert Steiner, M.D.
Chief Medical Officer
Robert (Bob) D. Steiner has more than 20 years of experience collaborating with industry in orphan and rare disease drug development. After 17 years at Oregon Health & Science University, most recently he served as Executive Director of the Marshfield Clinic Research Foundation (MCRF), Chief Scientific Officer for Marshfield Clinic, and Executive Associate Director of the University of Wisconsin Institute for Clinical and Translational Research (ICTR). He is currently Clinical Professor at the University of Wisconsin School of Medicine and Public Health (UWSMPH) where he continues a small practice and academic work. Bob has authored or coauthored more than 150 articles in peer-reviewed journals, the great majority focused on orphan and rare diseases. He was a member of the Institute of Medicine committee that published recommendations on Accelerating Rare Diseases Research and Orphan Product Development. Bob received his MD from the UWSMPH and completed residency at the Cincinnati Children’s Hospital Medical Center, followed by fellowship at the University of Washington and Seattle Children’s Hospital and Medical Center.
Chief Financial Officer
Harry Palmin has more than 20 years of corporate experience. He spent 15 years at Novelos Therapeutics (NVLT), where he served as President and CEO and Board Director, and built the company from concept to a $500M peak market cap; raised $98 million in funding; and oversaw ten clinical studies in oncology (including pivotal Phase 3 studies) and infectious diseases. Previously, he held roles at Lehman Brothers and Morgan Stanley.
Pamela M. Williamson, RAC, FRAPS
Acting Vice President, Regulatory Affairs
Pamela Williamson, RAC, FRAPS, joins Acer with over 30 years of experience in regulatory affairs, quality assurance and compliance, pharmacovigilance, clinical and product development and manufacturing operations with the biopharmaceutical industry. Prior to joining Acer, Pam was senior vice president of global regulatory affairs and patient safety at Alexion Pharmaceuticals where she was responsible for supporting the development of late stage internal research and development and external business development efforts. During her tenure at Genzyme Corporation, Pam was senior vice president of regulatory affairs and corporate quality systems followed by senior vice president, global head, for regulatory affairs and compliance where she was responsible for optimizing approval timelines and maximizing the value of the international product portfolio and pipeline. Prior to that, she held several positions with Serono and Ares-Serono, where she directed numerous cross-functional, multilevel teams. She led strategic and operational aspects of regulatory affairs, directed finished drug product technology transfer, manufacturing, operations logistics, and materials management. Pam is a member of the board of trustees for the Albany College of Pharmacy and Health Sciences and a member of the Pharmaceutical Research and Manufacturers of America, Biotechnology Industry Organization, Massachusetts Biotechnology Council, Food and Drug Law Institute, Drug Information Association, and Regulatory Affairs Professionals Society (Fellow). She has an MBA from Northeastern University in Boston.
Acting Chief Business Officer
Jeff Davis has more than 25 years of business and corporate development expertise as well as orphan drug expertise; and has led or supported over thirty transactions with an aggregate value in excess of $1 billion across all major therapeutic platforms. He is a Partner at Extera Partners; and previously held roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly.
Director, Program Management
Darren Allender has 13 years of experience in the biotech industry. His prior roles include serving as Project Manager at Bend Research; various CMC and project management positions at Seattle Genetics, where he served as Program & Alliance Manager, Associate CMC Project Manager, Senior Research Associate and Quality Control Analyst. He also held positions at Alidex.